Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diagnamed HoldingsDGNMF +3.24% Cash Ratio is 0.58 as of Jun. 2026, which is 16% below its 10-year median of 0.69. The stock has 1 warning sign investors should review. Among 662 Healthcare Providers & Services companies, Diagnamed Holdings ranks better than 50% on this metric.
Diagnamed Holdings has a Cash Ratio of 0.58. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Diagnamed Holdings's Cash Ratio or its related term are showing as below:
DGNMF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.19 Med: 0.69 Max: 15.72
Current: 0.58
During the past 5 years, Diagnamed Holdings's highest Cash Ratio was 15.72. The lowest was 0.19. And the median was 0.69.
DGNMF's Cash Ratio is ranked better than 50% of 662
companies
in the Healthcare Providers & Services industry
Industry Median: 0.58
vs DGNMF: 0.58
Diagnamed Holdings (OTCPK:DGNMF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Diagnamed Holdings Cash Ratio Related Terms
Diagnamed Holdings Cash Ratio Historical Data
* Premium members only.
The historical data trend for Diagnamed Holdings's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diagnamed Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnamed Holdings Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnamed Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Diagnamed Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnamed Holdings (DGNMF) has a Cash Ratio of 0.58 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Diagnamed Holdings and its competitors. This is 16% below median its historical median of 0.69. Over the past decade, Diagnamed Holdings' Cash Ratio has ranged from 0.19 to 15.72. According to the industry distribution chart, Diagnamed Holdings ranks #331 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 50%.
Is Diagnamed Holdings' Cash Ratio too high?
Diagnamed Holdings' current Cash Ratio of 0.58 is 16% below median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 15.72. The Healthcare Providers & Services industry median Cash Ratio is 0.58. Diagnamed Holdings' value of 0.58 is 0% at this industry median. Based on the distribution chart, Diagnamed Holdings ranks #331 out of 662 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Diagnamed Holdings' Cash Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnamed Holdings ranks #331 out of 662 companies for Cash Ratio. This puts Diagnamed Holdings in the upper half of its industry. The industry median Cash Ratio is 0.58. Diagnamed Holdings' value of 0.58 is 0% at this benchmark. Historically, Diagnamed Holdings' own Cash Ratio has ranged from 0.19 to 15.72 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 0.58, Diagnamed Holdings has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.58, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnamed Holdings's current Cash Ratio of 0.58 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Diagnamed Holdings and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnamed Holdings's current Cash Ratio is 0.58, which is 16% below median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnamed Holdings stock overvalued right now?
Diagnamed Holdings (DGNMF) has a current Cash Ratio of 0.58. The current Cash Ratio is 0.58, which is 16% below median its 10-year median of 0.69 and 0% at the Healthcare Providers & Services industry median of 0.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Diagnamed Holdings (DGNMF), the current Cash Ratio is 0.58 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGNMF has been successfully added to your 
